Matrix metalloproteinase and αvβ3 integrin-dependent vascular smooth muscle cell invasion through a type I collagen lattice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 4, 2000, Pages 998-1005

  Kanda, Shigeru ^a   Kuzuya, Masafumi ^a   Ramos, Miguel A ^a   Koike, Teruhiko ^a   Yoshino, Kohichiro ^b   Ikeda, Shoji ^b   Iguchi, Akihisa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Pharmacol Group R/D Labs   (Japan)

Author keywords

Cell migration; Collagen; Integrins; Matrix metalloproteinases; Smooth muscle cells

Indexed keywords

COLLAGEN TYPE 1; INTEGRIN; MATRIX METALLOPROTEINASE; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; COLLAGEN; ENZYME INHIBITOR; GELATINASE A; HYDROXAMIC ACID; KB R8301; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET-DERIVED GROWTH FACTOR BB; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VITRONECTIN RECEPTOR;

ANIMAL CELL; ARTICLE; CATTLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RESTENOSIS; SMOOTH MUSCLE FIBER; TUNICA MEDIA; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; ANIMAL; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; KINETICS; METABOLISM; PHYSIOLOGY; PROTEIN DENATURATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CATTLE; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; ENZYME INHIBITORS; HYDROXAMIC ACIDS; KINETICS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; MUSCLE, SMOOTH, VASCULAR; OLIGOPEPTIDES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN DENATURATION; RECEPTORS, VITRONECTIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0033625141     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.4.998     Document Type: Article

References (48)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Yoshida Y, Mitsuma M, Ling G, Jiang J, Shu Q. Migration of medial smooth muscle cells to the intima after balloon injury. Ann N Y Acad Sci. 1997;811:459-470.
3. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-1 and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 1994;93:1266-1274.
4. Skinner MP, Raines EW, Ross R. Dynamic expression of α1β1 and α2β1 integrin receptors by human vascular smooth muscle cells. Am J Pathol. 1994;145:1070-1081.
5. Bilato C, Curto KA, Monticone RE, Pauly RR, White AJ, Crow MT. The inhibition of vascular smooth muscle cell migration by peptide and antibody antagonists of the αvβ3 integrin complex is reversed by activated calcium/calmodulin-dependent protein kinase II. J Clin Invest. 1997;100:693-704.
6. Heickendorff L. Laminin, fibronectin and type IV collagen in BM-like material from cultured arterial smooth muscle cells. Int J Biochem. 1988;20:381-386.
7. Ross R, Klebanoff SJ. The smooth muscle cell, I: in vivo synthesis of connective tissue proteins. J Cell Biol. 1971;50:159-171.
8. de Reeder EG, Poelmann RE, van Munsteren JC, Patterson DF, Gittenberger-de-Groot AC. Ultrastructural and immunohistochemical changes of the extracellular matrix during intimai cushion formation in the ductus arteriosus of the dog. Atherosclerosis. 1989;79:29-40.
9. Newby AC, Gerge SJ. Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis. Curr Opin Cardiol. 1996;11:574-582.
10. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, Crow MT. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994;75:41-54.
11. Sperti G, van Leeuwen RTJ, Quax PHA, Maseri A, Kluft C. Cultured rat aortic vascular smooth muscle cells digest naturally produced extra-cellular matrix. Circ Res. 1992;71:385-392.
12. Kenagy RD, Vergel S, Mattsson E, Bendeck M, Reidy MA, Clowes AW. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol. 1996;16:1373-1382.
13. Carmeliet P, Moons L, Herbert J-M, Crawley J, Lupu F, Lijnen R, Collen D. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res. 1997;81:829-839.
14. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol. 1996;16:28-33.
15. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res. 1996;78:38-43.
16. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 1997;91:439-442.
17. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science. 1995;268:233-239.
18. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996;84:345-357.
19. Yamamoto M, Yamamoto M, Aoyagi M, Yamamoto K. Identification of integrins involved in cell adhesion to native and denatured type I collagens and the phenotypic transition of rabbit arterial smooth muscle cells. Exp Cell Res. 1995;219:249-256.
20. Melchiori A, Albini A, Ray JM, Stetler-Stevenson WG. Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. Cancer Res. 1992;52: 2353-2356.
21. Ward RV, Hembry RM, Reynolds JJ, Murphy G. The purification of tissue inhibitor of metalloproteinase-2 from its 72 kDa progelatinase complex. Biochem J. 1991;278:179-187.
22. Olson MW, Gervasi DC, Mobashery S, Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem. 1997;272: 29975-29983.
23. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777-1783.
24. Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ebata T, Wada Y, Ikeda S, Yoshino K, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K. A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice. Blood. 1997;90:542-548.
25. Matsumoto H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 1994;90:2203-2206.
26. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan U. Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist Gpen GRGDSPCA*. J Vasc Surg. 1994;19: 125-134.
27. Basson CD, Kocher O, Basson MD, Asis A, Madri JA. Differential modulation of vascular cell integrin and extracellular matrix expression in vitro by TGF-β1 correlates with reciprocal effects on cell migration. J Cell Physiol. 1992;153:118-128.
28. Janet MF, Argraves WS, Liau G. Regulation of vascular smooth muscle cell integrin expression by transforming growth factor β1 and by platelet-derived growth factor-BB. J Cell Physiol. 1992;151:588-595.
29. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. J Clin Invest. 1995;95: 713-724.
30. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993;7:1434-1411.
31. Kenagy RD, Hart CE, Stetler-Stevenson WG, Clowes AW. Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. Circulation. 1997;96: 3555-3560.
32. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
33. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
34. Webb KE, Henney AM, Anglin S, Humphries SE, McEwan JR. Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. Arterioscler Thromb Vasc Biol. 1997;17:1837-1844.
35. Jenkins GM, Crow MT, Bilato C, Gluzband Y, Ryu W-S, Li Z, Stetler-Stevenson W, Nater C, Froehlich JP, Lakatta ED, Cheng L. Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation. 1998;97:82-90.
36. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, Kronberger A, He CS, Bauer EA, Goldberg GI. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen. J Biol Chem. 1988;263:6579-6587.
37. Strongin AY, Collier I, Bannikov BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72 kDa type IV collagenase. J Biol Chem. 1995;270:5331-5338.
38. Will HW, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic domain of membrane type I metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. J Biol Chem. 1996;271:17119-17123.
39. Aimes R, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. J Biol Chem. 1995;270:5872-5876.
40. Gilles C, Polette M, Seiki M, Birembaut P, Thompson EW. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest. 1997;76:651-660.
41. Sato H, Takino T, Okada Y, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature. 1994;370:61-65.
42. Richard OH. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
43. Davis G. Affinity of integrins for damaged extracellular matrix: αvβ3 binds to denatured collagen type I through RGD sites. Biochem Biophys Res Commun. 1992;182:1025-1031.
44. Montgomery AMP, Reifeld RA, Cheresh DA. Integrin αvβ3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA. 1994;91:8856-8860.
45. Coleman KR, Braden GA, Willingham MC, Sane DC. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (αvβ3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ Res. 1999;84:1268-1276.
46. Hosiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. αvβ3 integrin expression in normal and atherosclerotic artery. Circ Res. 1995; 77:1129-1135.
47. Schneller M, Vuori K, Ruoslahti E. αvβ3 integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF. EMBO J. 1997;16:5600-5607.
48. Woodard AS, Garcia-Cardena G, Leong M, Madri JA, Sessa WC, Languino LR. The synergistic activity of αvβ3 integrin and PDGF receptor increases cell migration. J Cell Sci. 1998;111:469-478.